Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
Goldschmidt
H
H
Medizinische Klinik und Poliklinik V, Universität Heidelberg, Hospitalstrasse 3, 69115 Heidelberg, Germany. hartmut_goldschmidt@med.uni-heidelberg.de
Sonneveld
P
P
Cremer
F W
FW
van der Holt
B
B
Westveer
P
P
Breitkreutz
I
I
Benner
A
A
Glasmacher
A
A
Schmidt-Wolf
I G D
IG
Martin
H
H
Hoelzer
D
D
Ho
A D
AD
Lokhorst
H M
HM
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011446:Prospective Studies; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000008:administration & dosage*
D013792:Thalidomide; D003907:Dexamethasone; D004317:Doxorubicin